A blood test conducted in a prehospital setting may rapidly distinguish between ischemic and hemorrhagic stroke, potentially facilitating more rapid, targeted treatment. The test measures the levels ...

PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...

An ultra-sensitive blood test that reflects brain damage after acute ischemic stroke - and also predicts functional outcome. This is a discovery that is expected to be of great significance in the ...

Thrombolytic agents, including tenecteplase, are generally used within 4.5 hours after the onset of stroke symptoms. Information on whether tenecteplase confers benefit beyond 4.5 hours is limited. We ...

Mobile stroke units (MSUs) are ambulances with staff and a computed tomographic scanner that may enable faster treatment with tissue plasminogen activator (t-PA) than standard management by emergency ...

Background Few studies have investigated patient-reported non-motor outcomes after stroke in young adults. We aimed to assess ...